Table 3.
Clinical characteristics of TLR2-negative and TLR2-positive patients
| Variable | TLR2-negative patients | TLR2-positive patients | |
|---|---|---|---|
| No. of patients (%) | 76 (63.87) | 43 (36.13) | |
| Rai stage | |||
| Low risk (stage 0) | 12 (15.79) | 13 (30.23) | |
| Intermediate-risk (stage I/II) | 48 (63.16) | 25 (58.14) | |
| High-risk (stage III/IV) | 16 (21.05) | 5 (11.63) | |
| ZAP-70 (cut-off 20%) | |||
| Positive (%) | 37 (48.68) | 14 (32.56) | |
| Negative (%) | 39 (51.32) | 29 (67.44) | |
| CD38 (cut-off 20%) | |||
| Positive (%) | 33 (43.42) | 15 (34.88) | |
| Negative (%) | 43 (56.58) | 28 (65.12) | |
| Cytogenetic abnormalities | |||
| del(17p13.1) and/or del(11q22.3) | 37 (48.68) | 12 (27.90) | |
| Isolated del(13q14) | 16 (21.05) | 19 (44.18) | |
| Without del(17p13.1) and del(11q22.3) and del(13q14) | 19 (25.01) | 10 (26.25) | |
| Not evaluated (%) | 4 (5.26) | 2 (4.65) | |
| Patients requiring therapy (%) | 28 (53.4) | 23 (43.49) | |
| Untreated patients (%) | 48 (46.6) | 20 (46.51) | |
| WBC count(G/L)a | 32.18 (9.86–330.56) | 26.65 (8.72–238.53) | p < 0.05 |
| Lymphocyte count (G/L)a | 20.26 (5.51–317.85) | 18.75 (5.74–231.39) | NS |
| LDH (IU/L)a | 356 (265–886) | 355 (274–734) | NS |
| Hemoglobin (g/dL)a | 13.5 (9.6–16.5) | 13.65 (9.2–66.3) | NS |
| Platelets (G/L)a | 174 (49–388) | 179 (49–295) | NS |
| β2M (mg/dL)a | 2.48 (1.30–8.73) | 2.24 (1.45–15.20) | NS |
| CD19+/CD5+/ZAP-70+ cells (%)a | 29.20 (0.37–64.29) | 14.08 (0.21–52.38) | p < 0.01 |
| CD19+/CD5+/CD38+ (%) cellsa | 22.40 (0.22–80.90) | 11.42 (0.25–68.52) | p < 0.01 |
ROC analysis was used to determine the most significant cut-off values of TLR2 (1.6%)
WBC white blood cell, LDH lactate dehydrogenase, β2M β2-microglobulin, NS not significant
aMedian (range)